Heterogenous mutation spectrum and deregulated cellular
pathways in aberrant plasma cells underline molecular pathology
of light-chain amyloidosis

J 2021

Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis

CHYRA, Zuzana; Tereza SEVIKOVA; Petr VOJTA; Janka PUTEROVÁ; Lucie KUBÍNOVÁ et al.

Základní údaje

Originální název

Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis

Autoři

Vydání

haematologica, Pavia, Ferrata-Storti Foundation, 2021, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 11.049

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/21:00122204

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

AL AMYLOIDOSIS

Štítky

14119612, 143180, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 5. 2022 11:40, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Light-chain (AL) amyloidosis (ALA) is a rare but fatal monoclonal gammopathy (MG) causing organ and tissue damage resulting from the deposition of misfolded immunoglobulin free light chains in the form of amyloid fibrils.1 In some cases, ALA coexists with multiple myeloma (MM) (ALA+MM), which is the second most common blood cancer and is caused by the proliferation of clonal plasma cells (PC).2 Due to insufficient knowledge of ALA and ALA+MM biology, therapeutic options have mirrored treatment regimens of MM, which focus on the elimination of clonal PC.3,4 We investigated the mutation and gene expression profiles in clonal aberrant PC (aPC) in order to better understand ALA and ALA+MM etiology and to clarify the molecular differences between individual MG diagnoses.

Přiložené soubory

1789122.pdf

Citovat

CHYRA, Zuzana; Tereza SEVIKOVA; Petr VOJTA; Janka PUTEROVÁ; Lucie KUBÍNOVÁ; Kateřina GROWKOVÁ; Jana FILIPOVA; Martina ZATOPKOVA; Sebastian GROSICKI; Agnieszka BARCHNICKA; Wieslaw WIKTOR-JEDRZEJCZAK; Anna WASZCZUK-GAJDA; Alexandra JUNGOVA; Aneta MIKULASOVA; Marian HAJDÚCH; Martin MOKREJŠ; Luděk POUR; Martin ŠTORK; Lubica HARVANOVA; Martin MISTRIK; Gabor MIKALA; Pawel ROBAK; Anna CZYZ; Jakub DEBSKI; Lidia USNARSKA-ZUBKIEWICZ; Artur JURCZYSZYN; Lukas STEJSKAL; Gareth MORGAN; Fedor KRYUKOV; Eva BUDINSKÁ; Michal SIMICEK; Tomas JELINEK; Matous HRDINKA a Roman HAJEK. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. haematologica. Pavia: Ferrata-Storti Foundation, 2021, roč. 106, č. 2, s. 601-604. ISSN 0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2019.239756.

@article{1789122,
   author = {Chyra, Zuzana and Sevikova, Tereza and Vojta, Petr and Puterová, Janka and Kubínová, Lucie and Growková, Kateřina and Filipova, Jana and Zatopkova, Martina and Grosicki, Sebastian and Barchnicka, Agnieszka and WiktorandJedrzejczak, Wieslaw and WaszczukandGajda, Anna and Jungova, Alexandra and Mikulasova, Aneta and Hajdúch, Marian and Mokrejš, Martin and Pour, Luděk and Štork, Martin and Harvanova, Lubica and Mistrik, Martin and Mikala, Gabor and Robak, Pawel and Czyz, Anna and Debski, Jakub and UsnarskaandZubkiewicz, Lidia and Jurczyszyn, Artur and Stejskal, Lukas and Morgan, Gareth and Kryukov, Fedor and Budinská, Eva and Simicek, Michal and Jelinek, Tomas and Hrdinka, Matous and Hajek, Roman},
   article_location = {Pavia},
   article_number = {2},
   doi = {https://doi.org/10.3324/haematol.2019.239756},
   keywords = {AL AMYLOIDOSIS},
   language = {eng},
   issn = {0390-6078},
   journal = {haematologica},
   title = {Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis},
   url = {https://haematologica.org/article/view/9744},
   volume = {106},
   year = {2021}
}

TY  - JOUR
ID  - 1789122
AU  - Chyra, Zuzana - Sevikova, Tereza - Vojta, Petr - Puterová, Janka - Kubínová, Lucie - Growková, Kateřina - Filipova, Jana - Zatopkova, Martina - Grosicki, Sebastian - Barchnicka, Agnieszka - Wiktor-Jedrzejczak, Wieslaw - Waszczuk-Gajda, Anna - Jungova, Alexandra - Mikulasova, Aneta - Hajdúch, Marian - Mokrejš, Martin - Pour, Luděk - Štork, Martin - Harvanova, Lubica - Mistrik, Martin - Mikala, Gabor - Robak, Pawel - Czyz, Anna - Debski, Jakub - Usnarska-Zubkiewicz, Lidia - Jurczyszyn, Artur - Stejskal, Lukas - Morgan, Gareth - Kryukov, Fedor - Budinská, Eva - Simicek, Michal - Jelinek, Tomas - Hrdinka, Matous - Hajek, Roman
PY  - 2021
TI  - Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis
JF  - haematologica
VL  - 106
IS  - 2
SP  - 601-604
EP  - 601-604
PB  - Ferrata-Storti Foundation
SN  - 03906078
KW  - AL AMYLOIDOSIS
UR  - https://haematologica.org/article/view/9744
N2  - Light-chain (AL) amyloidosis (ALA) is a rare but fatal monoclonal gammopathy (MG) causing organ and tissue damage resulting from the deposition of misfolded immunoglobulin free light chains in the form of amyloid fibrils.1 In some cases, ALA coexists with multiple myeloma (MM) (ALA+MM), which is the second most common blood cancer and is caused by the proliferation of clonal plasma cells (PC).2 Due to insufficient knowledge of ALA and ALA+MM biology, therapeutic options have mirrored treatment regimens of MM, which focus on the elimination of clonal PC.3,4 We investigated the mutation and gene expression profiles in clonal aberrant PC (aPC) in order to better understand ALA and ALA+MM etiology and to clarify the molecular differences between individual MG diagnoses.
ER  -

CHYRA, Zuzana; Tereza SEVIKOVA; Petr VOJTA; Janka PUTEROVÁ; Lucie KUBÍNOVÁ; Kateřina GROWKOVÁ; Jana FILIPOVA; Martina ZATOPKOVA; Sebastian GROSICKI; Agnieszka BARCHNICKA; Wieslaw WIKTOR-JEDRZEJCZAK; Anna WASZCZUK-GAJDA; Alexandra JUNGOVA; Aneta MIKULASOVA; Marian HAJDÚCH; Martin MOKREJŠ; Luděk POUR; Martin ŠTORK; Lubica HARVANOVA; Martin MISTRIK; Gabor MIKALA; Pawel ROBAK; Anna CZYZ; Jakub DEBSKI; Lidia USNARSKA-ZUBKIEWICZ; Artur JURCZYSZYN; Lukas STEJSKAL; Gareth MORGAN; Fedor KRYUKOV; Eva BUDINSKÁ; Michal SIMICEK; Tomas JELINEK; Matous HRDINKA a Roman HAJEK. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. \textit{haematologica}. Pavia: Ferrata-Storti Foundation, 2021, roč.~106, č.~2, s.~601-604. ISSN~0390-6078. Dostupné z: https://doi.org/10.3324/haematol.2019.239756.

Přehled o publikaci